A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

NCT ID: NCT01669070

Last Updated: 2017-06-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-15
• Study Completion Date: 2012-11-16

Brief Summary

The purpose of this study is to demonstrate dose proportionality of the FF (50 microgram (mcg), 100 mcg or 200 mcg), when administered as a single and repeat dose from the NDPI containing FF formulated with lactose. In addition, the aim of this study is to determine the absolute bioavailability of the FF single strip product using the high strength product administered as a single dose with multiple inhalations and using 250 mcg intravenous (IV) FF.

This is a, part-randomized, open-label, 4 way crossover study (4 periods) in healthy adult subjects. During each period, subjects will receive FF in the morning and serial pharmacokinetic (PK) sampling (for up to 10 days for the inhaled treatment and up to 3 days for the IV treatment) and safety assessments will be performed. Each period will be separated by a washout period of at least 7 days and a follow-up telephone call will occur 7 -14 days after the last dose of study drug. The total duration of the study will be approximately 13-14 weeks for each subject.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FF 50 mcg powder inhalation

Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.

Group Type: EXPERIMENTAL

FF, 50 mcg

Intervention Type: DRUG

Novel dry powder inhaler

FF 100 mcg powder inhalation

Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.

Group Type: EXPERIMENTAL

FF, 100 mcg

Intervention Type: DRUG

Novel dry powder inhaler

FF 200 mcg powder inhalation

Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.

Group Type: EXPERIMENTAL

FF, 200 mcg

Intervention Type: DRUG

Novel dry powder inhaler

FF 250 mcg IV

Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.

Group Type: EXPERIMENTAL

FF, 250 mcg

Intervention Type: DRUG

Intravenous

Interventions

FF, 50 mcg

Novel dry powder inhaler

Intervention Type: DRUG

FF, 100 mcg

Novel dry powder inhaler

Intervention Type: DRUG

FF, 200 mcg

Novel dry powder inhaler

Intervention Type: DRUG

FF, 250 mcg

Intravenous

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male or female subjects between 18 and 65 years of age and body mass index (BMI) within the range 18.5 to 29.0 kilogram/meter squared.
• Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and bilirubin < or =1.5x upper limit of normal (ULN).
• Female subjects of child bearing potential are eligible to enter if they are not pregnant and willing to use protocol-specified methods of contraception to prevent pregnancy during the study.
• Average QT duration corrected for heart rate by Fridericia's formula (QTcF) <450 millisecond.
• Forced Expiratory Volume in 1 Second (FEV1) > or = 85% predicted at screening.
• Current non-smokers
• Able to satisfactorily use the NDPI.

Exclusion Criteria

• Subjects must not have a systolic blood pressure above 145 milimeter(mm) of mercury(Hg) or a diastolic pressure above 85 mmHg at the screening visit.
• History of breathing problems in adult life confirmed by normal lung function parameters (≥85% predicted).
• Donation of more than 500 mL blood within a 56 day period.
• Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit.
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
• The subject treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness.
• The subject has a positive: drug/alcohol, Hepatitis, HIV screen.
• Abuse of alcohol.
• Subject having positive cotinine and urine alcohol test.
• Participated in >3 clinical trials in the previous 10 months (if male), or >2 clinical trials in the previous 10 months (if female), or the subject has participated in a study (including follow up) within 60 days prior to the first dosing day in the current study.
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Taken systemic, oral or depot corticosteroids less than 12 weeks or inhaled, intranasal or topical steroids less than 4 weeks before the screening visit.
• Use of prescription or non-prescription drugs.
• History of severe milk protein allergy, sensitivity to any of the study medications, including immediate or delayed hypersensitivity to any intranasal, inhaled or systemic corticosteroid therapy.
• Pregnant or lactating females.
• Unwillingness or inability to follow the procedures outlined in the protocol.
• Subject is mentally or legally incapacitated.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Groningen, , Netherlands

Countries

Netherlands

Study Documents

Document Type: Annotated Case Report Form

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Individual Participant Data Set

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Informed Consent Form

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Study Protocol

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Statistical Analysis Plan

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Dataset Specification

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Document Type: Clinical Study Report

For additional information about this study please refer to the GSK Clinical Study Register

View Document

Related Links

https://www.clinicalstudydatarequest.com

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Other Identifiers

115441

Identifier Type: -

Identifier Source: org_study_id